Novel alpha-glucosidase active inhibitor

Abstract

The invention discloses a novel alpha-glucosidase active inhibitor, belonging to the field of functional factors of functional foods and medicines; tea pigments in the invention can be used for strongly inhibiting alpha-glucosidase activity; the IC50 of alcohol-soluble theaflavin, the IC50 of thearubigin and the IC50 of theabrownin are 3.94 mu g / ml, 3.24 mu g / ml and 75.43 mu g / ml respectively; the half inhibition rate IC 50 of alcohol-soluble theaflavin, the half inhibition rate IC50 of thearubigin and the half inhibition rate IC50 of theabrownin are 8.19 mu g / ml, 4.50 mu g / ml and 6.98 mu g / ml respectively; the alpha-glucosidase inhibition effect of alcohol-soluble tea pigments or water-soluble tea pigments is far prior to that of the common hypoglycemic medicine, namely acarbose (acarbose IC50=1.04 mg / ml); and therefore, the novel alpha-glucosidase active inhibitor can be used as a food additive or a medicine for treating diabetes. Because of being pure natural pigments extracted from tea leaves, the tea pigments are safe, nontoxic and better in blood sugar decreasing effect; the advantages of the tea pigments are imponderable by acarbose; and therefore, the novel alpha-glucosidase active inhibitor has the application prospect for being developed into a health-care product or a novel hypoglycaemic medicine.

Description

technical field [0001] The invention relates to a novel alpha-glucosidase activity inhibitor, which belongs to the field of functional factors and medicines of functional foods. Background technique [0002] Diabetes is a global endocrine system disease characterized by hyperglycemia, of which type Ⅱ diabetes accounts for more than 90%. Lowering blood sugar levels is an important way to prevent and treat diabetes. Some studies predict that the number of diabetic patients in the world will increase from 171 million in 2000 to 366 million in 2030, and the incidence rate will remain high, while the number of diabetics in developing countries may double. According to the report of the International Diabetes Federation, 5 million people die from diabetes every year in the world. By the end of 2014, the cost of diabetes treatment has exceeded 566 billion. Therefore, the work of preventing and treating diabetes is urgent. [0003] α-glucosidase inhibitors can delay the conversion ...

AI Technical Summary

Problems solved by technology

Common hypoglycemic drugs—acarbose, miglitol, and voglibose are all chemically or semichemically synthesized. Although they have a certain hypoglycemic effect, there are bloating, diarrhea, and liver damage in clinical application. and other side effects, so we need to find α-glucosidase inhibitors with less natural side effects from nature

Images